Enteric Coating

The polymer layer remains intact in the acidic environment of the stomach but responds to the higher pH of the small intestine by dissolving. This change removes the barrier around the dosage form and permits the active ingredient to become available later in gastrointestinal transit. The coating therefore links release timing to local acidity rather than immediate exposure after administration.

The difference in acidity provides the trigger that distinguishes gastric passage from intestinal release. Resistance to stomach acid can prevent premature drug liberation, while dissolution at intestinal pH allows delivery farther along the gastrointestinal tract. This mechanism is particularly relevant when an active ingredient is vulnerable to acidic degradation or when release in the stomach could cause local irritation.

An immediately releasing formulation makes its active ingredient available without the pH-dependent delay created by the coating. Enteric coating instead postpones release during gastric transit and supports availability in the intestine. That distinction can influence drug stability, gastrointestinal tolerability, and the relationship between administration, food, gastric movement, and the eventual therapeutic effect.

By delaying liberation of the active ingredient, the formulation can affect when drug exposure begins and how closely that timing follows gastric transit. It may protect acid-sensitive compounds, reduce contact between the drug and the stomach lining, and support more predictable effects when food or movement through the stomach would otherwise alter release timing.

The coating can be applied to tablets, capsules, or drug particles, so the technology is not restricted to one physical dosage form. Formulation selection determines how the pH-responsive layer surrounds the active ingredient and how the product passes through the stomach. These options allow enteric protection to be incorporated into different pharmaceutical preparations.

A formulation first places the active ingredient in a tablet, capsule, or particle-based preparation, then applies a layer made from a pH-responsive polymer. The finished product is intended to remain protected during acidic gastric passage and release after reaching the higher-pH intestinal environment. The key design outcome is delayed, site-specific availability rather than immediate release.

This approach is useful when the active ingredient may degrade in stomach acid, when exposure could irritate the stomach lining, or when the intended target is in the intestine. It can also help separate drug release from food or gastric transit, which may support more predictable therapeutic effects during pharmacological evaluation and treatment.